Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/art.40427 | DOI Listing |
Publication Analysis
Top Keywords
editorial epratuzumab
4
epratuzumab reveille
4
reveille requiem?
4
requiem? teachable
4
teachable moments
4
moments lupus
4
lupus sjögren's
4
sjögren's syndrome
4
syndrome clinical
4
clinical trials
4
Similar Publications
Editorial: Epratuzumab: Reveille or Requiem? Teachable Moments for Lupus and Sjögren's Syndrome Clinical Trials.
Arthritis Rheumatol
May 2018
Cedars-Sinai Medical Center, David Geffen School of Medicine, University of California, Los Angeles.
Why, why, why de-lupus (does so badly in clinical trials).
Expert Rev Clin Immunol
November 2016
b Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation , Oklahoma City , OK , USA.
Article Synopsis
- The annual review of therapeutic monoclonal antibodies (mAbs) highlights about 350 mAbs in various stages of clinical development, focusing on those in active Phase 2/3 or Phase 3 studies.
- As of early 2013, 28 single mAbs and one mAb combination are on the "Antibodies to watch" list, targeting conditions like cancers, Alzheimer's disease, and inflammatory disorders.
- The combination of actoxumab and bezlotoxumab is specifically being tested in Phase 3 studies for treating Clostridium difficile infections.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!